




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 226% points. The greatest weakness of PUMA Biotechnology INC is the variable Other Revenues, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 427%, being 193% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	53,663
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	586
Liabilities, Non-Current	0
Other Assets	1,053
Other Compr. Net Income	0
Other Expenses	11
Other Liabilities	439
Other Net Income	-76
Other Revenues	0
Property and Equipment	682
Research and Development	826
Selling, General and Administrative Expense	9,320

Output Variable	Value in 1000 USD
Assets	55,398
Liabilities	1,026
Expenses	10,157
Revenues	0
Stockholders Equity	54,373
Net Income	-10,233
Comprehensive Net Income	-10,233
BaseVar	33,328
ECR before Limited Liability	384%
Economic Capital Ratio	427%